Comparative Effects of R- and S-equol and Implication of Transactivation Functions (AF-1 and AF-2) in Estrogen Receptor-Induced Transcriptional Activity by Shinkaruk, Svitlana et al.
Nutrients 2010, 2, 340-354; doi:10.3390/nu2030340 
 
nutrients 
ISSN 2072-6643 
www.mdpi.com/journal/nutrients 
Communication 
Comparative Effects of R- and S-equol and Implication of 
Transactivation Functions (AF-1 and AF-2) in Estrogen 
Receptor-Induced Transcriptional Activity  
 
Svitlana Shinkaruk 
1, Charlotte Carreau 
1, Gilles Flouriot 
2, Catherine Bennetau-Pelissero 
1 and 
Mylène Potier 
1,*
 
 
1   ENITA de Bordeaux, Unité Micronutriments Reproduction Santé, 1 Cours du Général de Gaulle, 
CS 40201, F-33175 Gradignan cedex, France; E-Mails: s-poix-shinkaruk@enitab.fr (S.S); 
chaqx@hotmail.com (C.C.); c-bennetau@enitab.fr (C.B.-P.);  
2   CNRS UMR 6026, 35042, Equipe "Récepteur des œstrogènes et destinée cellulaire", Rennes cedex, 
France; E-Mail: gilles.flouriot@univ-rennes1.fr 
 
*  Author to whom correspondence should be addressed: E-Mail: m-potier@enitab.fr. 
Received: 4 January 2010; in revised form: 20 February 2010 / Accepted: 25 February 2010 / 
Published: 15 March 2010 
 
Abstract:  Equol, one of the main metabolites of daidzein, is a chiral compound with 
pleiotropic effects on cellular signaling. This property may induce activation/inhibition of 
the estrogen receptors (ER)  or and therefore, explain the beneficial/deleterious effects 
of equol on estrogen-dependent diseases. With its asymmetric centre at position C-3, equol 
can exist in two enantiomeric forms (R- and S-equol). To elucidate the yet unclear 
mechanisms of ER activation/inhibition by equol, we performed a comprehensive analysis 
of ER and ER transactivation by racemic equol, as well as by enantiomerically pure 
forms. Racemic equol was prepared by catalytic hydrogenation from daidzein and 
separated into enantiomers by chiral HPLC. The configuration assignment was performed 
by optical rotatory power measurements. The ER-induced transactivation by R- and S-
equol (0.1–10 µM) and 17-estradiol (E2, 10 nM) was studied using transient transfections 
of ER and ERin CHO, HepG2 and HeLa cell lines. R- and S-equol induce ER 
transactivation in an opposite fashion according to the cellular context. R-equol and S-
equol are more potent in inducing ER in an AF-2 and AF-1 permissive cell line, 
respectively. Involvement of ER transactivation functions (AF-1 and AF-2) in these 
effects has been examined. Both AF-1 and AF-2 are involved in racemic equol, R-equol 
and S-equol induced ER transcriptional activity. These results could be of interest to find 
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a specific ligand modulating ER transactivation and could contribute to explaining the 
diversity of equol actions in vivo.  
Keywords:  equol; enantiomeric forms; estrogen receptor; transactivation function; 
phytoestrogens 
 
Abbreviations 
AF, transactivation function; DCM: dichloromethane; DMEM, Dulbecco’s modified Eagle medium; 
E2, 17-estradiol; equol, equol; ER, estrogen receptor; FCS, fetal calf serum; HRT, hormone 
replacement therapy; ICI, ICI 182,780; IPA: isopropyl alcohol; SEM, standard error to the mean; 
SERM, selective estrogen receptor modulator; TFA: trifluoroacetic acid; V, vehicle. 
1. Introduction  
Estrogens are used in hormonal replacement therapy (HRT) to prevent menopausal symptoms such 
as hot flushes, urogenital atrophy, but also osteoporosis in postmenopausal women. Unfortunately, 
HRT has not lived up to its potential to improve health in women. Estrogens have been associated with 
an increased incidence of breast and endometrial cancers, which has led to the use of antiestrogens and 
selective estrogen receptor modulators (SERM) such as tamoxifen and raloxifen, which exhibit a safer 
profile. However, since undesirable effects persist, numerous investigators continue to search for better 
SERM for HRT. Much research has been conducted into the health benefits of consuming soy foods, 
with soy isoflavones and soy protein being implicated as protective against a variety of diseases 
including heart and vascular diseases, osteoporosis and hormone-dependant cancers (such as those of 
the breast and prostate) [1-3]. Despite their popularity and putative health benefits, it is clear that we 
need to know much more about the molecular mechanisms, safety and efficacy of these compounds as 
natural SERM, before they can be recommended to postmenopausal women either as pharmaceutical 
or nutraceutical agents or as food additives. 
Equol [7-hydroxy-3-(4’-hydroxyphenyl)-chroman], is a non-steroidal estrogenic compound found in 
high concentrations in the urine of about 40% of the adults consuming soy foods [4]. Equol, beside o-
desmethyl angolensin, is produced by the colonic bacterial biotransformation of the soy isoflavones 
aglycone daidzein [5-8]. Equol is a chiral molecule with an asymmetric centre at position C-3 and can 
occur in two enantiomeric forms, R- and S-equol. The absolute configuration of natural (-)-equol, 
produced by the intestinal bacterial flora, was assigned to S-configuration [9,10]. 
After the identification of equol in biological liquids, the total synthesis was of great importance in 
order to confirm the chemical structure, and then to provide a sufficient amount of this compound for 
biological activity studies. Racemic (±)-equol can be synthesized from daidzein and formonetin, which 
are readily available in sufficient quantities from plants or can be prepared by chemical synthesis. The 
key transformation step involves the reduction of a vinylogous ester to an ether group. The method 
most often used during the last years, was the hydrogenation of daidzein by hydrogen in acetic acid 
with 10% palladium on carbon as a catalyst [11,12]. Recently, transfer hydrogenation was proposed as 
an alternative to classic hydrogenation, and different catalysts were tested [13]. Paerlman’s catalyst Nutrients 2010, 2                                       
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(20% Pd(OH)2) was found to be highly effective in the reduction of formonetin, daidzein [13] and 
corresponding isoflavene [14]. A “biomimetic” reduction of formonetin with dihydroacridine as a 
hydride donor was also proposed [13]. Recently described, a new original synthetic approach to 
racemic equol provided a direct construction of the isoflavan skeleton via a Diels-Alder reaction of o-
quinone methides [15]. 
The pure S-equol enantiomer can be produced by microbiological methods [16,17]. The first total 
synthesis of S-equol was described only three years ago. This approach, based on an Evan alkylation 
and an intramolecular Bichwald etherification, needed the use of organolithium reagents for the 
alkylation step, which could not be improved and gave modest yield (9.8% of overall yield) [18]. A 
new alternative route employed allylic substitution and afforded the S-isomer in 24.6% yield over 13 
steps [19]. Both R- and S-equol of high stereoselective purity have been prepared by enantioselective 
hydrogenation of O-protected chromene in the presence of an Ir catalyst having a chiral ligand [20]. 
Therefore, all synthetic approaches to pure enantiomeric forms remain still expensive and time 
consuming. The semi-preparative chiral-phase HPLC provides ready and relatively rapid access to 
both S- and R-equol in quantity sufficient for in vitro studies [13,17,21,22]. 
Most of published results on the biological activities of equol in vitro are available for the racemate, 
with the exception of Magee et al. [22], who evaluated the effects of racemic equol and S-equol on 
breast and prostate cancer cell lines. Their main findings were that racemic and S-equol show 
equipotent biological effects on proliferation and invasion of these cell lines, while the compounds 
have different abilities to protect against induced DNA damage [22]. 
Equol is strikingly similar in chemical structure to estrogens and is therefore capable of binding 
weakly to estrogen receptors (ER) [23]. The effects of 17-estradiol (E2) and related compounds, such 
as non-steroidal estrogens and equol, are mediated by two members of the nuclear receptor 
superfamily, ER and ER, which are coded by separate genes. ERuse two transactivation functions 
(AF), located in their N-terminal (AF-1) and C-terminal (AF-2) domains. Once activated by ligand 
binding, these AF recruit co-regulators of gene transcription. The transcriptional activity of the AF-2 
region is dependent on ligand binding, while AF-1 is constitutively active when isolated. The 
transcriptional activity of ER can be promoted through functional cooperation between both AF-1 
and AF-2 or through each AF acting independently [24].  
Therefore, different forms of equol may produce clinical and/or experimental effects distinct from 
estrogens by differentially triggering ER transcriptional activity. To test this hypothesis, we have first, 
prepared the pure enantiomeric forms of equol, using semi-preparative chiral phase HPLC, in order to 
compare the effects of racemic equol and R- and S- enantiomers on the transcriptional activity of 
ERand ER Furthermore, the present study investigated the roles of the AF domains, and more 
particularly of the AF-1 domain, in the ability of R- and S-equol to induce ER transactivation. For 
these purposes, transient transfections of ER constructs were performed in ER-negative CHO, HeLa 
and HepG2 cell lines.  
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2. Results and Discussion 
2.1. Chemical Synthesis and Chiral Separation 
In this study, the racemic equol was prepared by catalytic hydrogenation from daidzein, which was 
synthesized as previously described [25]. R- and S-equol were then separated using a new chiral 
stationary phase Chiralpak® IA [26]. Different mobile phases were investigated (Table 1). The shorter 
retention times should be considered and a compromise between different chromatographic parameters 
should be found for providing an efficient semi-preparative separation. It was found that the mixture n-
heptane-isopropanol (n-Heptane/IPA (80/20, V/V)) had the highest potential in terms of 
enantioselective separation of equol with the retention of enantiomers in an appropriate time range 
(Figure 1). Loading studies have been run and scaled up to 10 mm diameter column. Good separation 
can be achieved with loading up to 7 mg of the racemate per injection. The best loading found in 
literature data was around 3 mg per injection [16]. 
Table 1. Examples of enantiomeric separations of racemic equol on chiral stationary phase 
Chiralpak® IA using different mobile phases. 
Eluent  Flow rate, mL/min  RT1  RT2   Rs 
MeOH/TFA (99.9/0.9)  0.5
a 18.59  20.32  1.11  1.27
n-Heptane/EtOAc/TFA (85/15/0.1)  1.0
a 34.56  40.13  1.18  2.58
n-Heptane/DCM/IPA/TFA (50/47.5/2.5/0.1) 1.0
a 27.94  32.04  1.17  3.09
n-Heptane/IPA (80/20)  1.0
a 9.14  10.37  1.22  2.83
n-Heptane/IPA (80/20)  3.0
b 13.41  15.17  1.17  3.92
a analytical column; 
b semi-preparative column. 
RT: retention time; : selectivity, or separation factor; Rs: resolution; TFA: trifluoroacetic acid; DCM: 
dichloromethane; IPA: isopropyl alcohol. 
Figure 1. Separation of equol enantiomers on Chiralpak® IA stationary phase. 
 
 
The optical rotations obtained from the isolated peaks 1 and 2 in methanol have positive ([]
20
589.3 = 
+17°) and negative ([]
20
589.3 = −25°) values, respectively. Since S-equol was reported to have a Nutrients 2010, 2                                       
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negative specific rotation ([]
20
589.3 = −23.5° in ethanol [18]), the order of elution was assigned as  
R-equol (peak 1) and then S-equol (peak 2). The enantiomeric purity of R- and S-equol were +99% and 
97.5%, respectively.  
2.2. Transcriptional Activation of ER by Different Enantiomeric Forms of Equol 
In CHO cells, racemic equol (0.1 µM to 10 µM) induces ER and ER transactivation on the ERE-
TK-LUC reporter gene in a dose-dependent fashion as calculated by linear regression (R
2 = 0.90 for 
ER and 0.95 for ER), as shown in Figure 2A. For ER a significant increase in transcriptional 
activity is obtained with 1 and 10 µM of racemic equol (3.4 ± 0.4-; 5.4 ± 1.4-fold increase compared to 
control, p < 0.05 and p < 0.01, respectively). For ER, only the highest concentration of racemic equol 
(10 µM) induces a significant effect (3.9 ± 1.3 fold increase compared to control, p < 0.05). Racemic 
equol (10 µM) induces a significant ER and ER transactivation similar to the one induced by 10 nM 
17-estradiol (E2), the endogenous ligand of ER. The ERinduced transactivation by E2 and racemic 
equol in CHO cells is slightly lower than that of ER (Figures 2B and C). E2 and equol effects on both 
ER and  are completely abolished by treatment with 1 µM ICI (data not shown). 
Figure 2. Transcriptional activation of ER by racemic equol in CHO cells. The effects of 
0.1, 1 and 10 µM of racemic equol on ER and ER transcriptional activities (A) and the 
effects of control (Vehicle (V), EtOH 0.01%), E2 (10 nM) and racemic equol (10 µM) on 
ER (B) and ER (C) transcriptional activities. Cells were co-transfected with ER or 
ER and the ERE-TK-LUC. Data are expressed as reporter fold induction compared to 
control. Shown are means ± SEM of 6–10 independent experiments, each performed in 
triplicate. Comparisons performed between experimental conditions are described in 
“Experimental Section”. Statistical significances are indicated by * or ** for comparison to 
control for p < 0.05 or p < 0.01, respectively. 
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We observe that similar effects to E2 are typically achieved at concentrations that are three-orders 
of magnitude higher, which can be reached physiologically with a soy-rich diet. This is in accordance 
with the fact that the relative binding affinity of racemic R- and S-equol measured on recombinant ER, 
is generally in the order of 100 to 1000-times less than that of E2 [13].  
Serum concentrations of equol are quite different between women (with an equol-producer status) 
from various geographic areas and/or specific diets. We have shown that serum concentrations of 
equol reach 0.6 µM following consumption of soy supplements and up to 3 µM after ingestion of 50 
mg total isoflavones (about 30% daidzin) twice a day [27,28]. A recent study demonstrated a high 
equol bioavailability, with racemic, R- and S-equol concentrations in plasma from 0.4 up to 2 µM after 
a single bolus administration of equol (20 mg) [29].  
We have previously demonstrated that the ability of phytoestrogens, such as genistein, daidzein 
and racemic equol to act as ER agonists is independent of the cellular context (AF-1 or AF-2 
permissive) [30]. Therefore, it was of particular interest to determine the mechanisms of action of 
enantiomeric forms of equol on ER transcriptional activation in epithelial cell lines, which have 
different AF permissiveness.  
In HepG2 cells, racemic equol, R-equol and S-equol (0.1 µM–10 µM) induce ER and ER 
transactivation on the ERE-TK-LUC reporter gene in a dose-dependent fashion, as calculated by linear 
regression (R
2 = 0.85; 0.95; 0.95 for ER and 0.90; 0.94; 0.78 for ER, respectively, data not shown). 
Racemic equol, R-equol and S-equol (10 µM) induce a significant ER and ER transcriptional 
activation (24.2 ± 5.2; 13.2 ± 0.4, 16.6 ± 2.1; and 10.9 ± 1.2; 30.5 ± 5.2; 13.3 ± 0.8 for ER and ER, 
respectively) compared to control, as shown in Figures 3A and B. In HepG2 cells, S-equol induces a 
higher ERtranscriptional activation than R-equol (p < 0.05). ER transcriptional activation induced 
by R-equol (10 µM) is not different from racemic equol. The ER-induced transactivation by R-equol, 
S-equol and racemic equol (10 µM) in HepG2 cells is overall lower than that of ERFigures 3A and 
B). There is no difference between racemic equol, R-equol and S-equol (10 µM) ERinduced 
transactivations in HepG2 cells. E2, racemic equol, R- and S-equol effects on both ER and ER are 
completely abolished by treatment with 1 µM ICI (data not shown).  
In HeLa cells, racemic equol and R-equol (0.1 µM-10 µM) induce ER and ER transactivation on 
the ERE-TK-LUC reporter gene in a dose-dependent fashion, as calculated by linear regression (R
2 = 
0.72; 0.78 for ER and 0.99; 0.78 for ER, respectively, data not shown). In contrast, S-equol even at 
the highest concentration tested (10 µM) does not induce significant ER transcriptional activation  
(1.8 ± 0.2 and 2.7 ± 0.9 for ER and ER, respectively) compared to control (Figures 3C and D). As 
for CHO cells (Figure 2), the ER and ERinduced transactivations by racemic equol (10 µM) in 
HeLa cells are similar (5.2 ± 1.4 and 5.4 ± 2.4 fold increase compared to control, p < 0.001 and  
p < 0.05, respectively). E2, racemic equol, R- and S-equol effects on both ER and ER are 
completely abolished by treatment with 1 µM ICI (data not shown). In HeLa cells, both ER and ER 
transcriptional activations induced by R-equol (10 µM) is not different from racemic equol. R-equol 
induces a stronger ERtranscriptional activation than S-equol (p < 0.01). Interestingly, the highest 
concentration of R-equol (10 µM) induces a stronger ER transcriptional activation than ER (10.0 ± 
0.7 and 2.9 ± 1.0 fold increase compared to control, p < 0.001 and p < 0.05, respectively). Nutrients 2010, 2                                       
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Figure 3. Transcriptional activation of ER by enantiomeric forms of equol in HepG2 (AF-
1 permissive) and HeLa (AF-2 permissive) epithelial cells. The effects of control (Vehicle 
(V), EtOH 0.01%), R- and S-forms and racemic equol (10 µM) on ER (A, C) and ER 
(B, D) transcriptional activities in HepG2 and HeLa cell lines, respectively. Cells were co-
transfected with ER or ER and the ERE-TK-LUC. Data are expressed as reporter fold 
induction compared to control. Shown are means ± SEM of 2–5 independent experiments, 
each performed in triplicate. Comparisons between experimental conditions are described 
in “Experimental section”. Statistical significances are indicated by * or *** for 
comparison to control for p < 0.05 or p < 0.001, respectively. 
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Taken together, our results clearly demonstrate that R-equol and S-equol induce ER and ER 
transactivations in a different manner in regards to the AF permissiveness of the cell line. While S-
equol is more potent to induce ER in the AF-1 (HepG2) permissive cell line, R-equol appears to be 
more effective in inducing ER in the AF-2 (HeLa) permissive cell line.  
Several studies have evaluated the ER subtypes binding affinity and/or transcriptional activity of 
racemic equol [10,31-33] and equol enantiomers [13]. Taken together these authors report that (1) in 
binding assays, equol has a distinctively higher binding affinity, but only slight preference for 
transactivation of ER compared to ER; (2) S–equol has a high binding affinity preference for ER 
while R-equol binds more weakly and with a preference for ER; (3) racemic, R- and S-equol are ER 
agonists in transcriptional activity studies, and (4) in contrast to the slight ER preference of R-equol, 
S-equol has no ER subtypes preference in terms of transcriptional potency [13]Nutrients 2010, 2                                       
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It is well known that the estrogenic potency of compounds is a complicated phenomenon, which 
results from a number of factors, such as the nature of the inducer, including antiestrogens, 
xenoestrogens and phytoestrogens, but also the differential effects on the transactivation functionalities 
of the receptor, the particular co-activators recruited, the cell- and target promoter-contexts, the relative 
expression of each ER subtype [34-39] and the cell differentiation stage [34,37,40,41]. Therefore, the 
use of different model to study transcriptional potencies (HEC-1 cell line and an (ERE)2-PS2-LUC 
reporter gene [13] versus HeLa and HepG2 cell lines and (ERE)-TK-LUC reporter gene, for instance, 
may also explain this discrepancy.  
The use of ER constructs expressed in ER-negative backgrounds has been a powerful technique 
for studying the function of various domains in the ER [37,40,41]. To further examine the role of AF-1 
in the ER-induced transactivation by R- and S-equol, we used expression vectors of full length ER 
(ER) or truncated ER in the A/B domain (ERAF-1) in both epithelial cell lines. We compared 
the transcriptional efficiency of both ER constructs on estrogen sensitive reporter genes in HepG2 
(AF-1 permissive) and HeLa (AF-2 permissive) epithelial cell lines. Similar expression of the different 
ER variants was controlled by Western blots as previously described [42].  
In HepG2 cells, where ER transactivation is mainly ensured by AF-1 (ER>>ERAF-1), 
racemic, R-and S- equol (10 µM) induce, as expected, a higher transactivation of ER than ERAF-1 
(Figure 4A). S-equol induces a higher ERAF-1 transcriptional activation than R-equol (p < 0.05) in 
AF-1 permissive cells. In HeLa cells, ER transactivation is mainly ensured by AF-2 
(ER≈ERAF-1). Racemic equol and R-equol (10 µM) induce a similar transactivation of both 
ER and ERAF-1 (Figure 4B), indicating that deletion of AF-1 has no effect on ER-induced 
transactivation for both compounds. Similar results are obtained in CHO cells (data not shown) with 
racemic equol presenting a similar transactivation profile as E2, as previously described [30]. In 
contrast, S-equol does not induce similar transcriptional activation of ER and ERAF-1 in HeLa 
cells. Deletion of AF-1 enhances ER transcriptional activity to reach the level of the one induced by 
racemic equol and significantly different than R-equol (p < 0.05, Figure 4B). This result indicates that 
this property of S-equol to induce ER transcriptional activation through AF-2 is partly repressed by 
AF-1. This could be due to a conformational change of the ligand binding domain, which inhibits, at 
least partially, the activity of AF-1 in HeLa cells [24]. ICI (1 µM) completely blocked the effects of E2 
and enantiomeric forms of equol in both cell lines (data not shown). R- and S-equol are therefore 
capable of inducing ER transactivation through activation of both AF, however, S-equol effect 
through AF-2 may be repressed by AF-1.  
Taken together, our results indicate that while R-equol and S-equol are more potent in inducing 
ER transactivation in an AF-2 and in an AF-1 permissive cell line, respectively, both compounds R-
equol and S-equol are capable of inducing ER transactivation through activation of both AF-1 and 
AF-2 domains. However, in contrast to R-equol,  S-equol-induced ER transcriptional activation 
through AF-2 is (1) higher in the AF-1 permissive cell line, and (2) partly repressed by AF-1 in the 
AF-2 permissive cell line. 
We conclude that racemic, R- and S-equol exert distinct effects on ER transcriptional activity, 
which cannot be solely explained by their differential affinities for the ER subtypes [13], but may be 
due to the differential effects on the transactivation functionalities of the receptor and the cell 
differentiation stage [30,34,37,40-42]. Given the pleiotropic actions of phytoestrogenic compounds, it Nutrients 2010, 2                                       
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is possible that they are also affecting other biological processes in addition to these mechanisms, such 
as cellular metabolism, relative expression of each ER subtype, non-genomic activities of ER or other 
signal transduction pathways (such as MAPK). Further in vitro studies are therefore needed to 
elucidate the pathways involved in equol effects. 
Figure 4. Transcriptional activation of ER and ERAF-1 by enantiomeric forms of 
equol in HepG2 (AF-1 permissive) and HeLa (AF-2 permissive) epithelial cells. The 
effects of R- and S-forms and racemic equol (10 µM) on ER and ERAF-1 transcriptional 
activities in HepG2 (A) and Hela (B) cell lines, respectively. Cells were co-transfected 
with ER or ERAF-1 and the ERE-TK-LUC. Data are expressed as reporter fold 
induction compared to control (Vehicle (V), EtOH 0.01%). Shown are means ± SEM of  
2-5 independent experiments, each performed in triplicate. Comparisons between 
experimental conditions were performed as described in methods section. Statistical 
significance for comparison between ER constructs or between R- and S-equol is indicated 
by *** for p < 0.001 or by ° for p < 0.05, respectively. 
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Approximately 40% of Humans have the bacteria capable of producing equol. The ability to 
produce equol following ingestion of soy isoflavones is of particular interest, because it has been 
demonstrated  in vitro and in some animal models that equol is more biologically active than its 
precursor daidzein and the alternate metabolite, o-desmethyl angolensin [5-8]. More importantly, 
studies report relationships between the equol-producer phenotype and reduced risk factors for several 
chronic diseases and differential responses to interventions (for review, [7,43]). Given that it is 
exclusively the S-equol enantiomer that is produced in vivo by the gut microflora, [9,10], our findings 
may have implications regarding the effects of equol in vivo. In particular, since ER activity is 
mediated through AF-1 in differentiated cells and through AF-2 in well-dedifferentiated cells [41], S-
equol may differentially modulate processes involving ERactivation, such as cell differentiation 
and/or proliferation, as in breast cancer. Nutrients 2010, 2                                       
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In this regard, a very recent study demonstrated, in a rat model of chemically-induced-tumors, that 
S-equol has no chemopreventive action in vivo, while the unnatural enantiomer R-equol was potently 
chemopreventive [44]. It is clear that further studies are needed to elucidate specifically the biological 
(for example, antigenotoxic and/or antioxidant properties) of such compound. However, these results 
may contribute to explain the diversity of daidzein and/or equol actions in vivo and particularly as S-
equol, as food supplement, is being clinically developed for the treatment of prevention of menopausal 
symptoms [45]. 
3. Experimental Section 
3.1. Chemicals and Instruments 
All chemical reagents and solvents were purchased from Sigma Aldrich Chemical Co. (Saint 
Quentin Fallavier, France), Alfa Aesar. (Bisheim, France), or Acros Organics France (Noisy, France). 
17-estradiol (E2) was purchased from Sigma Aldrich Chemical Co. (Saint Quentin Fallavier, France) 
and ICI 182,780, (ICI) from Tocris (United Kingdom). For cell culture, DMEM culture medium and 
fetal calf serum (FCS) were from Sigma Aldrich Chemical Co. (Saint Quentin Fallavier, France) while 
antibiotics and DMEM/F12 phenol red free medium were purchased from Invitrogen (France). 
FuGENE
TM 6 for transient transfections was provided by Roche Diagnostics (France). 
Melting points were determined with a Stuart Scientific melting point apparatus SMP3 and are 
uncorrected. 
1H and 
13C NMR spectra were recorded with a Bruker AC-300 FT (
1H: 300 MHz, 
13C: 75 
MHz). The chemical shifts () and coupling constants (J) are expressed in ppm and Hz, respectively. 
Optical rotations were measured on a Bellingham Stanley Polarimeter ADP220 at ambient 
temperature. Thin-layer chromatography (TLC) was performed using SDS TLC plates, 0.25 mm, 
particle size 15 m, pore size 60 Å. Merck silica gel 60 (70–230 mesh) and (0.063–0.200 mm) were 
used for flash chromatography. The spots were visualized with a UV lamp. 
3.2. Chemical Synthesis of (±)-Equol 
Palladium-on-charcoal (10%, 0.5g) was added to a well-stirred solution of daidzein (2 g, 7.9 mmol) 
in 95% ethanol (200 mL). The mixture was degassed and placed under hydrogen atmosphere at room 
temperature and atmospheric pressure for 24 h. After filtration and evaporation of the solvent, the 
crude product was recrystallized from ethanol/water to afford the target product as white crystals   
(1.2 g, yield 82%, purity ≥ 97%, m.p. 156–156.5 °C (lit. 158 °C [11])).  
1H NMR (acetone-d6, 300 MHz):  2.84 (m, 2H, H-4), 3.11 (m, 1H, H-3), 3.93 (dd, 
2J2ax-2eq = 
3J 2ax-3 
= 10.5 Hz, 1H, H-2ax), 4.19 (ddd, 
2J2ax-2eq = 10.5 Hz, 
3J2eq-3 = 3.6, 
4J2eq-4ax = 1.8, 1H, H-2eq), 6.30. (d, 
4J 
= 2.3 Hz, 1H, Har-8), 6.37 (dd, 
3J = 8.3 Hz, 
4J = 2.3 Hz, 1H, Har-6), 6.83 (d, 
3J = 8.6 Hz, 2H, Har-
3’,5’), 6.90 (d, 
3J = 8.3 Hz, 1H, Har-5), 7.16 (d, 
3J = 8.6 Hz, 2H, Har-2’,6’), 8.19 (br s, 1H, OH), 8.31 
(br s, 1H, OH). 
13C NMR (acetone-d6, 75 MHz):  156.7 (CQ-4’), 156.3 (CQ-9), 155.1 (CQ-7), 132.5 (CQ-1’), 
130.1 (CHar-5), 128.3 (CHar-2’,6’), 115.4 (CHar-3’5’), 113.2 (CQ-10), 107.9 (CHar-6), 102.7 (CHar-
8), 70.7 (CH2-2), 37.9 (CH-3), 31.8 (CH2-4). Nutrients 2010, 2                                       
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3.3. Chromatographic Resolution of R- and S- equol. 
Enantiomeric separation was performed on a Varian Prostar chromatographic system with UV 
detection at a wavelength of 280 nm. A Daicel Chiralpack
® IA column [26] with amylase tris (3,5-
dimethylphenylcarbamate chiral phase immobilized on 5 µm silica-gel (analytical column 250 × 4.6 
mm, semi-preparative column 250 × 10 mm, Chiral Technologie Europe, Illkirch, France) with a 
Chiralpak
® IA guard column were used. The mobile phase selected for the method consisted of a 
mixture of n-heptane/IPA (80/20, v/v) delivered in isocratic elution mode. The flow rates were 1 
mL/min and 3 mL/min for analytical and semi-preparative columns, respectively. For semi-preparative 
separation, the injection volume was 100 µL of equol solution in IPA (50 mg/mL). The elution order 
and retention times were as follows: RT 9.14 min for R-equol and RT 10.37 min for S-equol. 
3.4. Plasmids 
Expression vectors pSG5, pSG human (h)ER, pSGERAF-1 and pCMV-galactosidase as well 
as ERE-TK-LUC reporter genes were previously described [42]. Expression vector for human (h)ER 
(pSG5ER) was provided by Pr. J.A. Gustafsson’s department (Dpt Biosciences and Medical 
Nutrition, Karolinska Institute, Sweden). 
3.5. Cell Culture and Transient Transfection Experiments 
CHO, HeLa and HepG2 cell lines were routinely maintained in DMEM supplemented with 5% FCS 
and antibiotics. For experimental conditions, phenol red free medium DMEM/F12 supplemented with 
2.5% charcoal-stripped FCS was used (Experimental medium).  
Transfections were carried out with FuGENE
TM 6 as described previously [42] with 50 ng of total 
DNA consisting of the expression vector, the reporter gene and the pCMV- galactosidase internal 
control (10, 20 and 20 ng, respectively). Cells were treated either with different concentrations of E2 
and equol (10 nM and 0.1 to 10 µM, respectively), ICI (1 M) or vehicle (V, 0.01% EtOH), or a 
combination of these compounds as indicated. Cells were harvested and luciferase and -galactosidase 
assays were performed as previously described [42]. The reporter gene activity was obtained after 
normalization of the luciferase activity with the -galactosidase activity. 
3.6. Statistical Analysis 
Shown are the means ± SEM of 2 to 10 independent experiments, each performed in triplicate as 
indicated. One-way ANOVA and Dunnett’s multiple comparison post-hoc test or Student’s t-test were 
performed for the statistical analysis between experimental conditions (GraphPad Prism
®, USA). 
Dose–dependant effects were assessed by linear regression (GraphPad Prism
®, USA). Statistical 
significance is indicated by 1, 2, and 3 symbols (* or ◦) corresponding to p < 0.05, p < 0.01 and p < 
0.001, respectively. 
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4. Conclusions  
Equol, one of the main metabolites of daidzein is being clinically developed as a food supplement to 
treat estrogen-related diseases. Understanding how natural estrogenic compounds elicit clinical 
selective effects is key to the development of safer HRT. Equol is a chiral compound, and induction of 
activation/inhibition of the ER may depend on the enantiomeric form and purity of equol. Catalytic 
hydrogenation of daidzein followed by chiral HPLC separation provided ready and rapid access to 
racemic, R- and S- forms of equol in sufficient quantities, and allowed us to examine their differential 
effects on the two ER subtypes. Good chiral separation with semi-preparative isolation of more than 3 
mg of each enantiomer per injection was achieved using a new immobilized chiral stationary phase. 
We have shown that high concentrations (10 µM) of R-equol and S-equol induce ERand ER 
transcriptional activation differently according to the cellular context. R-equol and S-equol are more 
potent to induce ER in the AF-2 and AF-1 permissive cell lines, respectively. The S-enantiomer has 
little transcriptional potency on both ER and ER in an AF-2 permissive cell line. ER 
transcriptional activation by both ennatiomers involves their capacity to act mainly through AF-1 and 
AF-2. This study confirms that racemic, R-  and  S-  equol are SERM with estrogenic activities. 
Therefore, in light of our study of the effects of equol and its enantiomeric forms on the two ER, it 
would appear prudent to evaluate carefully, in vivo, the biological effects of not only the isoflavones, 
but also their metabolites and their enantiomers. Such investigations would greatly help in evaluating 
the potential effects of the ingestion of soy isoflavones on human health and disease.  
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